A magnetic nanoparticle including a TRPV1 agonist, as well as methods of preparation and use, are described herein. A magnetically responsive pharmaceutical can include a core region having a magnetic nanoparticle (MNPs) and a TRPV1 protein agonist. Further, an exterior coating comprising a polymer can be formed around the core region. The magnetically responsive pharmaceutical can be administered to a recipient and directed to a target region using an external magnetic field.

The disclosed bead vectors direct entry into a cell of monocytic origin and cause the expression of an extracellular domain of PD-1, an anti-CTLA4 antibody, or an antibody that is specific for a checkpoint protein. The bead vectors can comprise a nucleic acid component, a lysosome evading component and a bead particle that can be phagocytized. The disclosed vectors are useful in various methods of cancer therapy, treatment, and prevention. Due to the ability of monocytic cells to target tumors, the disclosed vectors are particularly well suited for use in anti-tumor applications and directing expression of target genes in tumor-associated macrophages.

Magnetosomes for use in a sequential laser radiation medical treatment, wherein the magnetosomes are administered to a body part of an individual. In a first step, the magnetosomes are irradiated by a laser radiation, and in a second step, the magnetosomes are irradiated by a laser radiation of lower power than in the first step or no laser irradiation of the magnetosomes is performed. The sequence of the first step and second step is repeated at least once.

Methods and systems for synthesizing multicompartment capsules are disclosed, as well as multicompartment polymer capsules formed in accordance with disclosed techniques. At least one plurality of polymer capsules are formed via a capsule-forming process. A feed solution and a reservoir solution are provided, each comprising a biopolymer. The feed solution biopolymer and the reservoir solution biopolymer have opposite charges. Droplets of the feed solution are introduced into the reservoir solution, thereby forming via electrostatic complexation a plurality of polymer capsules. At least a portion of the resulting polymer capsules are then encapsulated in a larger polymer capsule via a similar process, wherein the feed solution utilized for the encapsulation process also comprises the formed smaller capsules.

A magnetic nanoparticle including a TRPV1 agonist, as well as methods of preparation and use, are described herein. A magnetically responsive pharmaceutical can include a core region having a magnetic nanoparticle (MNPs) and a TRPV1 protein agonist. Further, an exterior coating comprising a polymer can be formed around the core region. The magnetically responsive pharmaceutical can be administered to a recipient and directed to a target region using an external magnetic field.

A method for manufacturing a biocompatible fluid including a powder of magnetic particles of elongated shape having a magnetic shape anisotropy and having a final granulometry, the final granulometry being defined by a first average size of the particles in a first direction and a second average size in a second direction different from the first direction, the final granulometry further being defined by a first distribution width of the first sizes and a second distribution width of the second sizes, the method including from a powder of magnetic particles having an initial granulometry different from the final granulometry, modification of the initial granulometry by milling and/or by sintering of the powder until the final granulometry is obtained; introduction of the powder of magnetic particles into a biocompatible fluid.

A self-healing polymeric material includes a polymeric matrix material, wherein dispersed within the polymeric matrix material is a mixture of materials that includes monomers and a photoinitiator, and a plurality of light generating microcapsules dispersed in the polymeric matrix material. Each light generating microcapsule encapsulates multiple reactants that undergo a chemiluminescent reaction. The chemiluminescent reaction generates a photon having a wavelength within a particular emission range that is consistent with an absorption range of the photoinitiator.

Normal or genetically modified cell(s) having magnetic nanoparticle(s) bound (affixed) to their surfaces and methods of delivery to target tissues, e.g. for treatment of disease and/or injury.

Compositions and methods for treating various cardiovascular disorders include targeted delivery of glutamate for impairing a targeted portion of the autonomic nervous system (ANS). Targeted delivery may be via direct injection into the targeted portion of the ANS or via vascular injection of magnetically-targetable nanoparticles.

A self-healing polymeric material includes a polymeric matrix material, a plurality of monomer mixture microcapsules dispersed in the polymeric matrix material, and a plurality of light generating microcapsules dispersed in the polymeric matrix material. Each monomer mixture microcapsule encapsulates a mixture of materials that includes monomers and a photoinitiator. Each light generating microcapsule encapsulates multiple reactants that undergo a chemiluminescent reaction. The chemiluminescent reaction generates a photon having a wavelength within a particular emission range that is consistent with an absorption range of the photoinitiator.